Ad
Wednesday, 18 April 2018
Experts query case for GlaxoSmithKline's new 3-in-1 lung drug
LONDON (Reuters) - Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment